TICKERNERD
Menu
LTRNLTRNHealthcare · Biotechnology

LTRN Stock Forecast: Lantern Pharma, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$2.61
−0.76% on the day

The 2 Wall Street analysts covering Lantern Pharma, Inc. hold a median 12-month price target of $20 — +666.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$33.6M
Ticker Nerd rank
68 / 100
Median analyst target
$20
Analysts covering
2
Total return, dividends reinvested
1W
−6.5%
1M
−34.3%
YTD
−13.9%
1Y
−45.3%
From 52W high
−50.9%
From 52W low
+133.0%
$1.12
$5.32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LTRN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lantern Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Growth
79
Issuance
72
Revisions
65
Value
55
Accruals
54
Momentum
53
Quality
19
Volatility
16

Size (85): Smaller than most of the companies we track.

Volatility (16): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Lantern Pharma, Inc. — and when they’d sell — is the membership.

Wall Street

LTRN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LTRN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26LTRNHigh $25Median $20Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $15Median $20High $25

The green dot is the last close — the median target sits +666.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Apr 2025Lake StreetInitiatesBuy—
2 Apr 2025Lake StreetInitiatesBuy$25
25 Apr 2024HC Wainwright & Co.ReiteratesNeutral—
10 Aug 2023EF HuttonReiteratesBuy—
26 June 2023EF HuttonMaintainsBuy—
25 May 2023EF HuttonAssumesBuy$11
18 May 2023HC Wainwright & Co.InitiatesNeutral—
21 Mar 2023EF HuttonReiteratesBuy—
15 Feb 2023EF HuttonMaintainsBuy—
1 Nov 2022EF HuttonInitiatesBuy—
11 Mar 2022HC Wainwright & Co.MaintainsBuy—
2 Nov 2021HC Wainwright & Co.MaintainsBuy—
7 Oct 2021HC Wainwright & Co.InitiatesBuy—
28 July 2020Colliers SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

LTRN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Lantern Pharma, Inc. (LTRN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
8.6×

Cheaper than 12% of US stocks

EV / EBITDA
−1.4×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−157.4%

Higher than 8% of US stocks

Return on assets
−73.3%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LTRN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LTRNLantern Pharma, Inc.$33.6M
68
NTRBNutriband, Inc.$34.3M
17
LITSLite Strategy, Inc.$34.4M
30
CRVOCervoMed, Inc.$34.9M
22
ENLVEnlivex Ltd.$35.2M
22
VERUVeru, Inc.$36.0M
46
CALCCalciMedica, Inc.$30.7M
36
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LTRN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest LTRN news & analysis

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

Business Wire · 3 Aug 2026positive

Lantern Pharma (Nasdaq: LTRN) launched Open-Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform for the transformation of medicine. The new entity was established through a separation from Lantern Pharma, according to the announcement.

Why it matters — LTRN watchers would care because the company is expanding and commercializing its AI platform through a newly formed separate entity, which broadens the reach of its technology.

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Business Wire · 28 July 2026positive

Lantern Pharma is advancing its EMA-cleared Phase 1b/2 clinical trial of LP-184 (Zirdafulven) for biomarker-selected advanced bladder cancer.

Why it matters — This trial advancement signals that Lantern Pharma is progressing LP-184, a key pipeline candidate, into a later-stage study for a specific cancer population in a major regulatory region.

FAQ

Frequently asked questions about LTRN stock

What is the LTRN stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Lantern Pharma, Inc. have a median 12-month price target of $20, with estimates ranging from $15 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LTRN stock a buy right now?

Of the 2 analysts covering Lantern Pharma, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lantern Pharma, Inc. 68 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LTRN?

As at 1 Aug 2026, Lantern Pharma, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

Will LTRN stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +666.3% from the last close, and Ticker Nerd's factor model ranks Lantern Pharma, Inc. 68 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LTRN stock forecast for 2030?

No analyst covering Lantern Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LTRN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $25 over the next 12 months.

How has LTRN stock performed over the past year?

Lantern Pharma, Inc. returned -45.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lantern Pharma, Inc. do?

Lantern Pharma Inc. is a clinical-stage biotechnology company specializing in oncology drug discovery and development through artificial intelligence, machine learning, and genomics.

What is the latest news on LTRN?

The most recent item we track (Business Wire, 3 Aug 2026): "Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine". Lantern Pharma (Nasdaq: LTRN) launched Open-Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform for the transformation of medicine. The new entity was established through a separation from Lantern Pharma, according to the announcement.

Company

About Lantern Pharma, Inc.

Lantern Pharma Inc. is a clinical-stage biotechnology company specializing in oncology drug discovery and development through artificial intelligence, machine learning, and genomics. At its core is the proprietary RADR platform, which analyzes hundreds of billions of oncology-focused data points and over 200 advanced machine learning algorithms to identify biomarkers, predict drug responses, design clinical trials, and accelerate the development of precision cancer therapies for solid tumors and blood cancers. The company's pipeline features lead candidates such as LP-300 in phase 2 trials for non-small cell lung cancer in never-smokers, LP-184 in phase 1 for solid tumors including pancreatic, breast, bladder, lung, glioblastoma, and other CNS cancers, and LP-284 in phase 1 for non-Hodgkin’s lymphomas like mantle cell and double hit lymphoma, alongside an ADC program spanning 12 cancer indications. Lantern Pharma Inc. focuses on stratifying patients into responders and non-responders to de-risk trials, develop companion diagnostics, and target genetically defined subsets with high unmet needs. Founded in 2013 and headquartered in Dallas, Texas, it operates at the intersection of AI and precision oncology to transform drug development processes.

CEO Mr. Panna Sharma · 16 employees · United States · https://www.lanternpharma.com